PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
12.50%
Net income growth above 1.5x TRVN's 1.36%. David Dodd would see a clear bottom-line advantage if it is backed by stable operations.
-31.48%
Negative yoy D&A while TRVN is 0.00%. Joel Greenblatt would note a short-term EPS advantage unless competitor invests for future advantage.
-66.70%
Both lines show negative yoy. Martin Whitman would see an industry or cyclical factor reducing tax deferrals for both players.
10.78%
SBC growth well above TRVN's 5.40%. Michael Burry would flag major dilution risk vs. competitor’s approach.
-179.22%
Negative yoy working capital usage while TRVN is 98.15%. Joel Greenblatt would see more free cash if revenue remains unaffected, giving a short-term advantage.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-302.85%
Negative yoy AP while TRVN is 100.00%. Joel Greenblatt would see quicker payments or less reliance on trade credit than competitor, unless expansions are hindered.
-91.10%
Negative yoy usage while TRVN is 82.14%. Joel Greenblatt would see a short-term advantage in freeing up capital unless competitor invests effectively in these lines.
10.78%
Some yoy increase while TRVN is negative at -6.57%. John Neff would see competitor possibly reining in intangible charges or revaluations more effectively than we do.
-32.84%
Negative yoy CFO while TRVN is 37.88%. Joel Greenblatt would see a disadvantage in operational cash generation vs. competitor.
-1.01%
Both yoy lines negative, with TRVN at -1540.52%. Martin Whitman would suspect a cyclical or broad capital spending slowdown in the niche.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-1225.23%
We reduce yoy other investing while TRVN is 30.61%. Joel Greenblatt sees a near-term cash advantage unless competitor’s intangible or side bets produce strong returns.
-1611.06%
We reduce yoy invests while TRVN stands at 4.60%. Joel Greenblatt sees near-term liquidity advantage unless competitor’s expansions yield high returns.
No Data
No Data available this quarter, please select a different quarter.
-0.50%
Negative yoy issuance while TRVN is 0.31%. Joel Greenblatt sees a near-term advantage in avoiding dilution unless competitor invests more effectively with the new shares.
No Data
No Data available this quarter, please select a different quarter.